Form 4: AbbVie EVP Roopal Thakkar Acquires Shares and Options Under Incentive Plans

Roopal Thakkar, EVP, R&D and CSO of AbbVie, reports the acquisition of shares and options related to performance-based awards and an incentive stock program.

Summary

• Roopal Thakkar, an Executive Vice President at AbbVie, filed a Form 4 detailing changes in beneficial ownership of AbbVie stock.
• On February 13, 2025, Thakkar acquired a total of 10,555 shares of AbbVie common stock related to performance share and restricted stock unit awards.
• These shares were issued under awards granted in 2022, 2023 and 2024, with performance-vesting restrictions based on earnings per share and relative return on equity.
• The performance goals were certified by the Compensation Committee of AbbVie's Board of Directors, leading to the release of the restrictions.
• The shares will be issued to Thakkar on February 28, 2025.
• Thakkar also acquired an option to buy 25,000 shares of AbbVie common stock at an exercise price of $192.86, granted under the 2013 Incentive Stock Program.
• The option becomes exercisable in annual increments starting February 13, 2026.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of performance-based awards suggests the company is meeting its goals, and the stock options align executive interests with shareholders.

Positives

• The vesting of performance-based awards suggests that AbbVie has met certain performance targets related to earnings per share and relative return on equity.
• The grant of stock options aligns Thakkar's interests with those of shareholders, incentivizing him to drive long-term value creation.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and exercisability schedules of the awards.

Industry Context

Executive compensation through stock awards and options is a common practice in the pharmaceutical industry to align management's interests with shareholder value. Performance-based vesting is also a standard feature to incentivize the achievement of specific financial or strategic goals.

Comparison to Industry Standards

• AbbVie's use of performance-based equity awards aligns with industry practices among large-cap pharmaceutical companies such as Johnson & Johnson, Pfizer, and Merck.
• These companies often utilize metrics like earnings per share (EPS) and total shareholder return (TSR) as key performance indicators for vesting equity grants.
• The vesting schedules and option terms are generally consistent with industry norms for executive compensation packages.

Stakeholder Impact

• Shareholders may view the vesting of performance-based awards positively, as it indicates the company is achieving its performance targets.
• Employees may be motivated by the fact that executives are incentivized to drive company performance.
• The transactions have no immediate impact on customers, suppliers, or creditors.

Key Dates